New pill takes on tough cancers: first human trial begins

NCT ID NCT06403436

Completed Disease control Sponsor: TOLREMO therapeutics AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a first-in-human trial, so the effects are still unknown.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TT125-802 (a drug taken by mouth)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) and small study (50 people), so the drug may not prove safe or effective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer disease neoplasm non-small cell lung carcinoma squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT DISEASE ADULT SOLID TUMOR ADVANCED SOLID TUMOR CANCER EGFR KRAS G12C NSCLC SQUAMOUS CELL LUNG CANCER

Contacts and locations

Locations

Centre Hospitalier Universitaire Vaudois

Lausanne, 1890, Switzerland
Ente Ospedaliero Cantonale

Bellinzona, 6500, Switzerland
NEXT Oncology Barcelona

Barcelona, 08023, Spain
NEXT Oncology Madrid

Madrid, 28223, Spain
NEXT Oncology Virginia

Fairfax, Virginia, 22031, United States
Sarah Cannon Research Institute Oncology Partners

Nashville, Tennessee, 37203, United States
Vall d'Hebron Institute of Oncology

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.